MedicaidBilling CodesMedium impact
DSS Important Message - Reimbursement for COVID-19 Monoclonal Antibody Therapy
Connecticut Medicaid (HUSKY Health)·CT · Emergency Medicine, Infectious Disease·Provider Bulletin
Effective date
Aug 15, 2022
We identified it
Jun 20, 2026
Summary
Connecticut Medicaid (CMAP) will now reimburse hospitals for COVID-19 monoclonal antibody therapy bebtelovimab (Q0222) at 95% AWP ($2394) when commercially purchased from Eli Lilly (batch D534422), but hospitals should not bill for government-purchased batches.
Action Required
Immediately: Billing team must check bebtelovimab batch numbers before billing Q0222 to Connecticut Medicaid. Only bill Q0222 for batch D534422 (commercially purchased from Eli Lilly). Do not bill Q0222 for government-purchased batches. Continue monitoring Eli Lilly for future commercial batch numbers. Update billing protocols to verify batch numbers on vials.